Navigation Links
ADVENTRX Reports Third Quarter Financial Results
Date:11/8/2010

ne or ANX-514 if they receive regulatory approval; the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings, including prior to the filing or the approval of the Exelbine NDA or an NDA for ANX-514, which activities may increase the cost and timeline to NDA filing or approval and negatively impact ADVENTRX's ability to raise additional capital or partner its lead product candidates; the potential that changes made in transferring the manufacturing process for Exelbine and/or ANX-514 may result in a lack of comparability between the commercial product and the material used in bioequivalence trials, and that FDA may require ADVENTRX to perform additional non-clinical or clinical studies; the risk the FDA will determine that Exelbine and Navelbine® and/or ANX-514 and Taxotere® are not bioequivalent, including as a result of performing bioequivalence analysis based on a patient population other than the population on which ADVENTRX based its analysis or determining that increased docetaxel blood-levels during and immediately following infusion are clinically relevant; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing Exelbine and/or ANX-514, including validating commercial manufacturing processes and manufacturers, as well as suppliers, and the potential for automatic injunctions regarding FDA approval of ANX-514; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of the Exelbine and ANX-514 development programs, including analysis of the ANX-514 bioequivalence trial data, and that such third parties may fail to perform as expected; uncertainty regarding additional product candidates ADVENTRX may seek to acquire and the costs associated with developing and seeking approval of any such product candidates; the potential f
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
(Date:9/30/2014)... , Sept. 30, 2014   Decision ... patient-level claims data, anemic chronic kidney disease non-dialysis ... erythropoiesis-stimulating agent (ESA) medication. In addition, one-year persistency ... Other key findings from the ... An Analysis of Erythropoiesis Stimulating Agents in Late ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... On Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 ... Inc.,s (CTI) (NASDAQ and MTA: CTIC) management team will ... first quarter achievements and financial results. ... Central European/5:30 a.m. Pacific Time 1-800-762-8779 (US Participants) ...
... 2012  Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... version of FORTAMET® (metformin hydrochloride extended-release tablets) as part ... the product today. FORTAMET® is indicated as an adjunct ... patients 17 years of age or older. ...
Cached Medicine Technology:Watson Launches Generic FORTAMET(R) 2
(Date:9/30/2014)... some stickleback fish fathers can have long-term effects on ... dads cause their offspring to behave in a way ... changes are accompanied by changes in gene expression, the ... the Proceedings of the Royal Society B: Biological ... moms are very important for their offspring," said ...
(Date:9/30/2014)... Asheville, North Carolina (PRWEB) September 30, 2014 ... cloud readiness and IT Infrastructure analytics across data ... announced it has achieved an important milestone of ... problems and plan for important projects such as ... workload migrations. , The strong customer engagement ...
(Date:9/30/2014)... 2014 Speaking on this occasion, ... ‘Nursing Conference’ as a remarkable event, which brings together ... and clinical research and diagnostic companies, leading universities and ... perfect platform to share experience, foster collaborations across industry ... Nursing Conference is a forum to explore issues of ...
(Date:9/30/2014)... 2014 MyMobileUni seeks to partner globally ... have similar shared vision to transform individuals and empower ... (MMU):, , to impact ... all ages , to have focused channels ... to promote equal access to education and ...
(Date:9/30/2014)... with bowel cancer for a genetic condition would cut ... new research has found. , In a major study, ... and researchers from the University of Exeter,s Medical School ... for a genetic condition known as Lynch Syndrome. ... by changes in genes which check the spelling in ...
Breaking Medicine News(10 mins):Health News:In stickleback fish, dads influence offspring behavior and gene expression 2Health News:In stickleback fish, dads influence offspring behavior and gene expression 3Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 2Health News:Exploring New Possibilities to Take Nursing Profession to Great Heights 3Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 2Health News:MyMobileUniversity Call to Public and Private Organisations, NGOs’ and Individuals: Catalyze Positive Social Change, Let’s Transform Individuals and Empower Communities 3Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3
... one species of bacteria could be more persistent and ... other, encouraging it to bolster its defenses. Interrupting ... these infections. Researchers from Wake Forest University Baptist ... , the online open-access journal of the American Society ...
... ... Boise, Idaho acupuncture clinic, recently relocated to a larger office and more convenient ... acupuncture clinic is now located in very close proximity to one of the ... licensed acupuncturists and 2 massage therapists working collaboratively to help patients get and ...
... 2010 Elsevier, the world-leading publisher of scientific, technical ... Society of Geriatric Oncology (SIOG) announced today the launch ... www.geriatriconcology.net ). The journal is focused on advancing ... of older adults with cancer. It covers all ...
... ... health care organizations better comply with OASIS-C and improve staff performance and patient outcomes ... new and updated patient and caregiver teaching resources. , ... (PRWEB) July 6, 2010 -- Pritchett & Hull ...
... Site ... ... Surgery (ASAPS) is proud to introduce Project Beauty , a new consumer website, that ... one the leading medical authorities in Beauty - The American Society for Aesthetic Plastic Surgery., , ...
... ... Though Advanced Software Testing Services and Methodologies , ... Naples, FL (PRWEB) July 6, 2010 -- QualEDIx, a ... ICD-10 software testing services network is pleased to announce that healthcare industry veteran, Larry ...
Cached Medicine News:Health News:Bacterial communication encourages chronic, resistant ear infections 2Health News:Boise Acupuncture Clinic Grows into Larger Office 2Health News:Elsevier and International Society of Geriatric Oncology launch Journal of Geriatric Oncology 2Health News:Aesthetic Society Launches Project Beauty, ,NEW Consumer Website Covering All Things Beauty, 2Health News:Aesthetic Society Launches Project Beauty, ,NEW Consumer Website Covering All Things Beauty, 3Health News:Larry Watkins Joins QualEDIx as Executive Vice President, Healthcare Strategy and Business Development 2Health News:Larry Watkins Joins QualEDIx as Executive Vice President, Healthcare Strategy and Business Development 3
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 20-200 microliter range....
... and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: